共 99 条
- [1] Billingham L(2016)Research methods to change clinical practice for patients with rare cancers Lancet Oncol 17 e70-e80
- [2] Malottki K(2005)Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens J Clin Oncol 23 6982-6991
- [3] Steven N(2020)Response rates and durations of response for biomarker-based cancer drugs in nonrandomized versus randomized trials JNCCN J Natl Compr Cancer Netw 18 36-43
- [4] Zia MI(2014)Approval after phase I: ceritinib runs the three-minute mile Oncologist 19 577-578
- [5] Siu LL(2013)Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study Lancet Oncol 14 38-47
- [6] Pond GR(2017)Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial JAMA 317 1844-1853
- [7] Chen EX(2016)Sufficiency of single-arm studies to support registration of targeted agents in molecularly selected patients with cancer: lessons from the clinical development of crizotinib Clin Transl Sci 9 63-73
- [8] Gyawali B(2012)Role of randomized phase III trials in an era of effective targeted therapies Nat Rev Clin Oncol 9 208-214
- [9] D’Andrea E(2016)Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive metastatic non-small cell lung cancer Oncologist 21 974-980
- [10] Franklin JM(2018)Without randomized studies, the costeffectiveness of a therapy cannot be known Ann Oncol 29 527-529